Table of contents

  1. Front Matter
    Pages i-ix
  2. Tina L. Yuan, Lewis C. Cantley
    Pages 1-7
  3. José Ramón Bayascas
    Pages 9-29
  4. Elisabeth Fayard, Gongda Xue, Arnaud Parcellier, Lana Bozulic, Brian A. Hemmings
    Pages 31-56
  5. Klaus Okkenhaug, David A. Fruman
    Pages 57-85
  6. Lazaros C. Foukas, Dominic J. Withers
    Pages 115-141
  7. Esther Castellano, Julian Downward
    Pages 143-169
  8. Carlotta Costa, Emilio Hirsch
    Pages 171-181
  9. Phillip T. Hawkins, Len R. Stephens, Sabine Suire, Michael Wilson
    Pages 183-202
  10. Shaun P. Jackson, Simone M. Schoenwaelder
    Pages 203-224
  11. David A. Fruman
    Pages 225-244
  12. Kathryn Waite, Britta J. Eickholt
    Pages 245-265
  13. Back Matter
    Pages 301-308

About this book


From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here.


PDK1 PI3K TOR kinase domain inhibitor haematological malignancies malignant glioma oncogenesis oncoprotein

Editors and affiliations

  • Christian Rommel
    • 1
  • Bart Vanhaesebroeck
    • 2
  • Peter K. Vogt
    • 3
  1. 1.IntellikineLa JollaUSA
  2. 2., Institute of Cancer and the London SchooQueen Mary, University of LondonLondonUnited Kingdom
  3. 3., Dept. Molecular & Exp. MedicineScripps Research InstituteLa JollaUSA

Bibliographic information